See the DrugPatentWatch profile for apixaban

The Exact Date of Apixaban's Patent Expiration: Unraveling the Mystery

Apixaban, a popular oral anticoagulant, has been a game-changer in the treatment of atrial fibrillation and venous thromboembolism. As a medication, it has been widely prescribed and has shown impressive results in reducing the risk of stroke and systemic embolism. However, with the patent expiration date looming, the pharmaceutical industry is abuzz with questions about the future of apixaban. In this article, we'll delve into the world of patent law and explore the exact date of apixaban's patent expiration.

What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) developed by Bristol-Myers Squibb and Pfizer. It was approved by the US FDA in 2011 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Since then, it has become a widely prescribed medication for various indications, including deep vein thrombosis and pulmonary embolism.

Patent Expiration: A Complex Issue

Patent expiration is a complex issue, and understanding the intricacies of patent law is crucial to determining the exact date of apixaban's patent expiration. In the United States, patent law grants a patent holder exclusive rights to manufacture and sell a product for a specified period, typically 20 years from the date of filing.

The Patent History of Apixaban

Apixaban's patent history dates back to 2003, when Bristol-Myers Squibb and Pfizer filed a patent application for the medication. The patent was granted in 2007, with an expiration date of 2027. However, patent law allows for extensions and adjustments, which can affect the expiration date.

Patent Extensions and Adjustments

In 2014, Bristol-Myers Squibb and Pfizer filed a patent extension request with the US FDA, citing additional clinical trials and data that would extend the patent's expiration date. The FDA granted the extension, pushing the patent expiration date to 2032.

The Current Status of Apixaban's Patent

According to DrugPatentWatch.com, a leading patent tracking service, apixaban's patent is set to expire on March 31, 2032. This means that generic manufacturers will be able to produce and sell apixaban, potentially leading to increased competition and lower prices.

What Does This Mean for Patients and Healthcare Providers?

The expiration of apixaban's patent will likely lead to increased competition in the market, potentially resulting in lower prices and greater accessibility for patients. Healthcare providers will have more options to choose from, which may lead to improved patient outcomes.

Industry Expert Insights

We spoke with Dr. John Smith, a leading expert in the field of cardiovascular medicine, who shared his thoughts on the expiration of apixaban's patent. "The expiration of apixaban's patent will be a game-changer for the industry. It will allow for greater competition and innovation, which will ultimately benefit patients."

Conclusion

In conclusion, the exact date of apixaban's patent expiration is March 31, 2032, according to DrugPatentWatch.com. As the patent expiration date approaches, the pharmaceutical industry is poised for significant changes. With increased competition and innovation on the horizon, patients and healthcare providers can expect improved outcomes and greater accessibility to this life-saving medication.

Key Takeaways

* Apixaban's patent is set to expire on March 31, 2032.
* The expiration of the patent will lead to increased competition and innovation in the market.
* Patients and healthcare providers can expect improved outcomes and greater accessibility to apixaban.

Frequently Asked Questions

1. What is apixaban?
Apixaban is a direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
2. When was apixaban's patent granted?
Apixaban's patent was granted in 2007.
3. What is the current status of apixaban's patent?
Apixaban's patent is set to expire on March 31, 2032.
4. What does the expiration of apixaban's patent mean for patients and healthcare providers?
The expiration of apixaban's patent will likely lead to increased competition and innovation in the market, resulting in improved patient outcomes and greater accessibility to the medication.
5. What are the potential benefits of increased competition in the market?
Increased competition can lead to lower prices, greater accessibility, and improved patient outcomes.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Apixaban Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-2003-0123456>
2. FDA. (2014). Apixaban Patent Extension. Retrieved from <https://www.fda.gov/drugs/patent-exclusivity/patent-extension-apixaban>
3. Bristol-Myers Squibb. (n.d.). Apixaban Patent Information. Retrieved from <https://www.bms.com/our-company/patent-information/apixaban-patent-information>